Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Orthop. Mar 18, 2026; 17(3): 115155
Published online Mar 18, 2026. doi: 10.5312/wjo.v17.i3.115155
Published online Mar 18, 2026. doi: 10.5312/wjo.v17.i3.115155
Impact of pre-chemotherapy locomotive syndrome status on short-term adverse outcome events in elderly lung cancer patients: A longitudinal study
Dan-Hua Liang, Lan Li, Ying Chen, Yu-Ling Yang, Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi 214122, Jiangsu Province, China
Xiao-Rui Feng, Operating Room, Affiliated Hospital of Jiangnan University, Wuxi 214122, Jiangsu Province, China
Co-first authors: Dan-Hua Liang and Xiao-Rui Feng.
Author contributions: Liang DH, Feng XR, and Yang YL designed the research study; Feng XR, Li L, and Chen Y performed the research; Li L and Yang YL contributed new reagents and analytic tools; Liang DH and Feng XR analyzed the data and wrote the manuscript. Liang DH and Feng XR contributed equally to this manuscript and are co-first authors. All authors have read and approved the final manuscript.
Supported by Jiangsu Provincial Traditional Chinese Medicine Science and Technology Development Plan Project, No. MS2024063; Research Project on Hospital Management Innovation in Jiangsu Province, No. JSYGY-3-2024-601; the Regional Medical Center Development Program Under the Partnership Between Jiangnan University Affiliated Hospital and Donghai County People’s Hospital, No. DHBFH202501 and No. DHBFH202503; and the Scientific and Technological Achievements Promotion Project of Wuxi Municipal Health Commission Project Program, No. LCYJ202336.
Institutional review board statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Affiliated Hospital of Jiangnan University, No. LS2023101.
Clinical trial registration statement: This study is registered at ChiCTR.org.cn, registration number: No. ChiCTR2400079958 (available from: https://www.chictr.org.cn/bin/home).
Informed consent statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: The datasets used during the current study are available from the corresponding author on reasonable request.
Corresponding author: Yu-Ling Yang, PhD, Department of Oncology, Affiliated Hospital of Jiangnan University, No. 1000 Hefeng Road, Wuxi 214122, Jiangsu Province, China.
Received: October 14, 2025
Revised: November 10, 2025
Accepted: January 5, 2026
Published online: March 18, 2026
Processing time: 158 Days and 7.9 Hours
Revised: November 10, 2025
Accepted: January 5, 2026
Published online: March 18, 2026
Processing time: 158 Days and 7.9 Hours
Core Tip
Core Tip: Currently, more studies focus on the effects of nutritional, immune, or systemic functional status on chemotherapy toxicity and prognosis in elderly lung cancer patients. In contrast, research on the locomotive syndrome status of elderly lung cancer patients before chemotherapy is relatively scarce. In this study, we intend to investigate the locomotive syndrome status of elderly lung cancer patients before chemotherapy and analyze its impact on short-term adverse events.